Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94114


Purpose:

To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable subcutaneous regimen that will replicate the immunologic improvement demonstrated in the outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient population.


Study summary:

Patients will receive subcutaneous Proleukin, and the MTD will be determined.


Criteria:

Inclusion Criteria Patients must have: - Documented HIV infection by ELISA and Western blot. - CD4 count > 200 cells/mm3. Required: - FDA-approved antiretroviral therapy for at least 2 months prior to study entry.


NCT ID:

NCT00002107


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

San Francisco, California 94114
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.